Overview

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
An open, multicenter, phase Ib/II study to evaluate the efficacy, safety and pharmacokinetics of CT041 autologous CAR T-cell injection in patients with advanced gastric/ gastroesophageal junction adenocarcinoma and pancreatic cancer
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
CARsgen Therapeutics Co., Ltd.
Carsgen Therapeutics, Ltd.
Collaborators:
Beijing Cancer Hospital
Fudan University